Canaccord analyst Sumant Kulkarni raised the firm’s price target on Neurocrine to $164 from $154 and keeps a Buy rating on the shares. The firm said the key update for us from yet another solid quarter on Ingrezza execution was the company filed two new drug applications (NDA) for crinecerfont for adult and pediatric patients with congenital adrenal hyperplasia (CAH) and hopes to receive priority review.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine backs FY24 INGREZZA net product sales view $2.1B-$2.2B
- Neurocrine reports Q1 adjusted EPS $1.20, consensus $1.01
- Neurocrine Biosciences Reports First Quarter 2024 Financial Results
- Neurocrine announces FDA approval of INGREZZA SPRINKLE capsules
- Neurocrine management to meet with Oppenheimer
